MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

Search

Pacific Biosciences of California Inc

Closed

SectorHealthcare

1.11 -0.89

Overview

Share price change

24h

Current

Min

1.1

Max

1.12

Key metrics

By Trading Economics

Income

63M

2.4M

Sales

-743K

39M

EPS

-0.2

Profit margin

6.045

Employees

575

EBITDA

-123M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+85.84% upside

Dividends

By Dow Jones

Next Earnings

8 maj 2025

Market Stats

By TradingEconomics

Market Cap

355M

Previous open

2

Previous close

1.11

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Pacific Biosciences of California Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 kwi 2025, 23:53 UTC

Hot Stocks

Stocks to Watch: Starbucks, Snap, Super Micro Computer, Seagate Technology

29 kwi 2025, 23:06 UTC

Earnings

Prudential PLC 1Q New Business Profit Increases by 12%

29 kwi 2025, 23:00 UTC

Earnings

America Movil's Posts Rise in 1Q Profit, Revenue

30 kwi 2025, 00:00 UTC

Top News

Buffett's 'Woodstock for Capitalists' Draws Admirers From Around the Globe -- WSJ

29 kwi 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fears About U.S. Tariffs Ebb -- Market Talk

29 kwi 2025, 23:43 UTC

Market Talk

Gold Consolidates; Signs of Easing in U.S. Tariffs' Impact May Weigh -- Market Talk

29 kwi 2025, 23:41 UTC

Earnings

China Minsheng Banking 1Q Net Interest Income CNY24.87B Vs. CNY24.26B>1988.HK

29 kwi 2025, 23:41 UTC

Earnings

China Minsheng Banking 1Q Operating Income CNY36.81B Vs. CNY34.27B>1988.HK

29 kwi 2025, 23:41 UTC

Earnings

China Minsheng Banking 1Q Net CNY12.74B Vs. Net CNY13.45B >1988.HK

29 kwi 2025, 23:24 UTC

Earnings

China Vanke 1Q Rev CNY37.99B Vs. CNY61.59B >000002.SZ

29 kwi 2025, 23:24 UTC

Earnings

China Vanke: Increase in Investment Losses Also Hurt Results >000002.SZ

29 kwi 2025, 23:24 UTC

Earnings

China Vanke 1Q Loss CNY6.25B Vs. Loss CNY361.97M >000002.SZ

29 kwi 2025, 23:24 UTC

Earnings

China Vanke: Singificant Decline in Property Sales Weighed on Results >000002.SZ

29 kwi 2025, 23:24 UTC

Earnings

China Vanke 1Q Loss Widened Significantly >000002.SZ

29 kwi 2025, 23:15 UTC

Top News

UPS to Cut 20,000 Jobs After Amazon Breakup -- 2nd Update

29 kwi 2025, 23:14 UTC

Earnings

China Eastern Airlines 1Q Loss CNY995.0M Vs. Loss CNY803.0M >0670.HK

29 kwi 2025, 23:14 UTC

Earnings

China Eastern Airlines: Increased Competition in the Aviation Market Hurt Results >0670.HK

29 kwi 2025, 23:14 UTC

Earnings

China Eastern Airlines 1Q Rev CNY33.41B Vs. CNY33.19B >0670.HK

29 kwi 2025, 23:14 UTC

Earnings

China Eastern Airlines 1Q Loss Widened >0670.HK

29 kwi 2025, 23:11 UTC

Earnings

China Southern Airlines Swung to Loss in 1Q>1055.HK

29 kwi 2025, 23:11 UTC

Earnings

China Southern Airlines 1Q Rev CNY43.41B Vs. CNY44.60B >1055.HK

29 kwi 2025, 23:11 UTC

Earnings

China Southern Airlines: Shift in Traveler Demographics, Competition From High-Speed Rail Networks Also Hurt Results >1055.HK

29 kwi 2025, 23:11 UTC

Earnings

China Southern Airlines 1Q Loss CNY747.0M Vs. Net CNY756.0M >1055.HK

29 kwi 2025, 23:11 UTC

Earnings

China Southern Airlines: CNY Depreciation, Global Supply Chain Constraints Among Factors Weighing on Results >1055.HK

29 kwi 2025, 23:07 UTC

Earnings

Air China 1Q Rev CNY40.02B Vs. CNY40.07B >0753.HK

29 kwi 2025, 23:07 UTC

Earnings

Air China 1Q Losses Widened>0753.HK

29 kwi 2025, 23:07 UTC

Earnings

Air China 1Q Loss CNY2.04B Vs. Loss CNY1.67B >0753.HK

29 kwi 2025, 23:02 UTC

Earnings

COSCO SHIPPING Energy Transportation: Weaker Earnings In International Oil Tanker Fleet Business Weighed on Results>1138.HK

29 kwi 2025, 23:02 UTC

Earnings

COSCO SHIPPING Energy Transportation 1Q Net CNY707.70M Vs. Net CNY1.24B >1138.HK

29 kwi 2025, 23:02 UTC

Earnings

COSCO SHIPPING Energy Transportation 1Q Rev CNY5.75B Vs. CNY5.84B >1138.HK

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

85.84% upside

12 Months Forecast

Average 2.1 USD  85.84%

High 3 USD

Low 1.5 USD

Based on 10 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

5

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

1.13 / 1.15Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.